There are however, significant limitations in High-throughput screening (HTS) approach and with the advent of newer technologies it has become antiquated. When compared to a platform like SEE-TxTM  which uses molecular dynamics and proprietary druggability analysis to refine the compound pool, HTS requires a physical collection of millions of compounds, robots to handle the experiments, specialised analytic equipment, etc.
Gain Therapeutics’ algorithm is able to narrow down millions of compounds to 100-200 leads. It is much quicker to set up an assay to test 100 compounds than for millions of compounds. The former can be carried out in standard 96-well plates or using biophysical techniques that are not suitable for HTS (e.g. SPR), whereas the latter must be performed in ultra-miniaturised formats that take a lot of time and effort to set up. Typically, we find that 10% of the compounds we select are active. In HTS the hit rate is much lower (<0.1%).